Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma

Medicine and Dentistry

• Mutant 100%
• Lung Adenocarcinoma 100%
• Cells 12%
• Adenocarcinoma 12%
• Specimen 12%
• Lung Cancer 12%
• Toxicity 8%
• Tissues 8%
• Female 8%
• Diarrhea 8%
• Nausea 8%
• Mucositis 8%
• Population Research 4%
• Absence 4%
• Targeted Therapy 4%
• Exon 4%
• Epidermal Growth Factor Receptor 4%

Nursing and Health Professions

• Patient 100%
• Lung Adenocarcinoma 100%
• Afatinib 16%
• Poziotinib 16%
• Lung Cancer 12%
• Adenocarcinoma 12%
• Toxicity 8%
• Diarrhea 8%
• Nausea 8%
• Next Generation Sequencing 8%
• Mucosa Inflammation 8%
• Combination Therapy 4%
• Absence 4%

Biochemistry, Genetics and Molecular Biology

• Mutant 100%
• Mutation 29%
• Next Generation Sequencing 16%
• Sequencing 12%
• Gene Mutation 8%
• Exon 4%
• Population Research 4%